Immunotherapy for patients with malignant glioma: From theoretical principles to clinical applications

Expert Review of Neurotherapeutics

Volumn 6, Issue 10, 2006, Pages 1481-1494

  Yang, Meng Yin ^a   Zetler, Paul M ^a   Prins, Robert M ^a   Khan Farooqi, Haumith ^a   Liau, Linda M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies; Biomarkers; Brain tumor; Cancer; Dendritic cells; Glioma; Immunotherapy; Neoplasm; T lymphocytes; Vaccines

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARMUSTINE; COLONY STIMULATING FACTOR 1; DENDRITIC CELL VACCINE; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 13 PSEUDOMONAS EXOTOXIN CONJUGATE; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 4 PSEUDOMONAS EXOTOXIN CONJUGATE; INTERLEUKIN 6; INTERLEUKIN 7; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425 I 125; MONOCLONAL ANTIBODY 81C6 I 131; PSEUDOMONAS EXOTOXIN; TEMOZOLOMIDE; TENASCIN; TRANSFERRIN; TRANSFERRIN DIPHTHERIA TOXIN CONJUGATE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; GENETIC ANALYSIS; GLIOBLASTOMA; HEADACHE; HUMAN; ISOTOPE LABELING; LYMPHOKINE ACTIVATED KILLER CELL; NAUSEA; NONHUMAN; PASSIVE IMMUNIZATION; PATIENT SELECTION; PREVALENCE; RADIOIMMUNOTHERAPY; REVIEW; TUMOR IMMUNITY;

BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNIZATION, PASSIVE;

EID: 33750633141     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.10.1481     Document Type: Review

References (120)

1. Preston-Martin S, Davis F, McKean-Cowdin R. Epidemiology of primary brain tumors. In: Brain Tumor Immunotherapy. Liau LM, Becker DP, Cloughesy TF, Bigner DD (Eds.). Humana Press, NJ, USA, 47-71 (2001).
2. American Cancer Society. Cancer Facts and Figures 2005. American Cancer Society, GA, USA (2005).
3. Stewart LA. Chemotherapy in adult highgrade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018 (2002).
4. Sehati N, Liau LM. Adjuvant treatment for gliomas. Contemporary Neurosurgery 25, 1-9 (2003).
5. Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J. Control Release 74, 63-67 (2001).
6. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
7. Prins RM, Liau LM. Immunology and immunotherapy in neurosurgical disease. Neurosurgery 53, 144-152 (2003). Of special interest.
8. Walker PR, Calzascia T, Dietrich PY. All in the head: obstacles for immune rejection of brain tumours. Immunology 107, 28-38 (2002). Of considerable interest.
9. Wischhusen J, Schneider D, Mittelbronn M et al. Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. J. Neuroimmunol. 162, 28-42 (2005).
10. Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin. Cancer Biol. 13, 343-351 (2003).
11. Walker PR, Calzascia T, Schnuriger V et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J. Immunol. 165, 3128-3135 (2000).
12. Smits HA, van Beelen AJ, de Vos NM et al. Activation of human macrophages by amyloid-β is attenuated by astrocytes. J. Immunol. 166, 6869-6876 (2001).
13. Taniguchi Y, Ono K, Yoshida S, Tanaka R. Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect of glioma-derived factors on antigen presentation. J. Neuroimmunol 111, 177-185 (2000).
14. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia 36, 118-124 (2001). • Of special interest.
15. Nelson DJ, Mukherjee S, Bundell C et al. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J. Immunol. 166, 5557-5566 (2001).
16. Ochsenbein AF, Sierro S, Odermatt B et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
17. Aloisi F, Ambrosini E, Columba-Cabezas S, Magliozzi R, Serafini B. Intracerebral regulation of immune responses. Ann. Med. 33, 510-515 (2001).
18. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol. Today 21, 141-147 (2000).
19. Saas P, Boucraut J, Walker PR et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32, 102-107 (2000).
20. Saas P, Walker PR, Quiquerez AL et al. A self-defence mechanism of astrocytes against Fas-mediated death involving interleukin-8 and CXCR2. Neuroreport 13, 1921-1924 (2002).
21. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195, 1499-1505 (2002).
22. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 165, 4773-4777 (2000).
23. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2, 46-53 (2002).
24. Lampson LA. Brain tumor immunotherapy: an immunologist's perspective. J. Neurooncol. 64, 3-11 (2003). Of considerable inerest.
25. Walker PR, Calzascia T, de Tribolet N, Dietrich PY. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res. Rev. 42, 97-122 (2003).
26. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N. Engl. J. Med. 349, 1543-1554 (2003). Of special interest.
27. Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial Tcell responses modulated by the local CNS tumor microenvironment. Clin. Cancer Res. 11, 5515-5525 (2005).
28. Hohlfeld R, Wekerle H. Immunological update on multiple sclerosis. Curr. Opin. Neurol. 14, 299-304 (2001).
29. Dorries R. The role of T-cell-mediated mechanisms in virus infections of the nervous system. Curr. Top. Microbiol. Immunol. 253, 219-245 (2001).
30. Facoetti A, Capelli E, Nano R. HLA class I molecules expression: evaluation of different immunocytochemical methods in malignant lesions. Anticancer Res. 21, 2435-2440 (2001).
31. Yang I, Kremen TJ, Giovannone AJ et al. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-α and interferon-γ treatment of human glioblastoma multiforme. J. Neurosurg. 100, 310-319 (2004).
32. Nigro JM, Misra A, Zhang L et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 65, 1678-1686 (2005).
33. Tuteja R, Tuteja N. Serial analysis of gene expression (SAGE): application in cancer research. Med. Sci. Monit. 10, RA132-RA140 (2004).
34. Liau LM, Yang I. Microarrays and the genetic analysis of brain tumors. Current Genomics 3, 33-41 (2002). Of special interest.
35. Liau LM, Lallone RL, Seitz RS et al. Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. Cancer Res. 60, 1353-1360 (2000).
36. Van Meir EG, Hao C, Post DE, Liau LM, Brat DJ. Development of molecular therapy for specific targeting of the pathways that permit brain tumor development. In: Genomic and Molecular Neuro-Oncology. Zhang W, Fuller GN (Eds). Jones and Bartlett Publishers, MA, USA (2004). Of considerable interest.
37. Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol. Immunother. 50, 639-652 (2002).
38. Lutzker SG, Lattime EC. Use of dendritic cells to immunize against cancers overexpressing p53. Clin. Cancer Res. 7, 2-4 (2001).
39. Liu G, Yu JS, Zeng G et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J. Immunother. 27, 220-226 (2004).
40. Murayama K, Kobayashi T, Imaizumi T et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J. Immunother. 23, 511-518 (2000).
41. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain. Clin.Cancer Res. 8, 2851-2855 (2002).
42. Katoh M, Wilmotte R, Belkouch M et al. Survivin in brain tumors: an attractive target for immunotherapy. J. Neurooncol. 64, 71-76 (2003).
43. + T lymphocytes. Clin. Cancer Res. 10, 828-839 (2004).
44. Liu G, Ying H, Zeng G et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64, 4980-4986 (2004).
45. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. (2003).
46. Shai R, Shi T, Kremen TJ et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22, 4918-4923 (2003).
47. Mischel PS, Shai R, Shi T et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22, 2361-4973 (2003).
48. Jones LA, Salgaller ML. Immunologic approaches to antigen discovery for cancer vaccines. Expert Opin. Investig. Drugs 9, 481-490 (2000). Of special interest.
49. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol. 22, 516-523 (2001). Of special interest.
50. Butterfield LH, Meng WS, Koh A et al. T cell responses to HLA-A*0201-restricted peptides derived from human á fetoprotein. J. Immunol. 166, 5300-5308 (2001).
51. Maecker B, von Bergwelt-Baildon, Anderson KS, Vonderheide RH, Schultze JL. Linking genomics to immunotherapy by reverse immunology - 'immunomics' in the new millennium. Curr. Mol. Med. 1, 609-619 (2001).
52. Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther. 2, 242-247 (2003).
53. Freije WA, Castro-Vargas FE, Fang Z et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64, 6503-6510 (2004).
54. Prins RM, Liau LM. Cellular immunity and immunotherapy of brain tumors. Front. Biosci. 9, 3124-3136 (2004). Of considerable interest.
55. Mehrian-Shai R, Reichardt JK, Ya-Hsuan H et al. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res. Mol. Brain Res. 136, 99-103 (2005).
56. Salgaller ML. American Association for Cancer Research: dendritic cells: strategies and vaccines. April 1-5, 2000, San Francisco, CA, USA. Expert Opin. Investig. Drugs 9, 1407-1412 (2000).
57. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157 (2005).
58. Sampson JH, Crotty LE, Lee S et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl Acad. Sci. USA 97, 7503-7508 (2000).
59. Wikstrand CJ, Zalutsky MR, Bigner DD. Radiolabeled antibodies for therapy of brain tumors. In: Brain Tumor Immunotherapy. Liau LM, Becker DP, Cloughesy TF, Bigner DD (Eds). Humana Press, NJ, USA, 205-229 (2001).
60. Riva P, Franceschi G, Frattarelli M et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a Phase I study. Clin. Cancer Res. 5, S3275-S3280 (1999).
61. Reardon DA, Akabani G, Coleman RE et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin.Oncol. 20, 1389-1397 (2002).
62. Emrich JG, Brady LW, Quang TS et al. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am. J. Clin. Oncol. 25, 541-546 (2002).
63. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58, 972-975 (2004).
64. Paganelli G, Bartolomei M, Ferrari M et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16, 227-235 (2001).
65. Bartolomei M, Mazzetta C, Handkiewicz-Junak D et al. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q. J. Nucl. Med. Mol. Imaging 48, 220-228 (2004).
66. Hall WA. Targeted toxin therapy for malignant astrocytoma. Neurosurgery 46, 544-551 (2000).
67. Rand RW, Kreitman RJ, Patronas N et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin.Cancer Res. 6, 2157-2165 (2000).
68. Kunwar S. Convection-enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase I studies. Acta Neurochir. Suppl. 88, 105-111 (2003).
69. Parney IF, Kunwar S, McDermott M et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J. Neurosurg. 102, 267-275 (2005).
70. Sampson JH, Akabani G, Archer GE et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. 65, 27-35 (2003).
71. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92, 168-175 (2001).
72. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65, 37-48 (2003).
73. Kunwar S, Chang SM, Prados MD et al. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg. Focus 20, E15 (2006).
74. Shimamura T, Husain SR, Puri RK. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg. Focus 20, E11 (2006).
75. Plautz GE, Mukai S, Cohen PA, Shu S. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J. Immunol. 165, 3656-3662 (2000).
76. Plautz GE, Miller DW, Barnett GH et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin.Cancer Res. 6, 2209-2218 (2000).
77. Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer J. 9, 157-166 (2003).
78. Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62, 665-671 (1988).
79. Dillman RO, Duma CM, Schiltz PM et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J. Immunother. 27, 398-404 (2004).
80. Hayes RL, Arbit E, Odaimi M et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit. Rev. Oncol. Hematol. 39, 31-42 (2001).
81. Kruse CA, Cepeda L, Owens B et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45, 77-87 (1997).
82. Merchant RE, Baldwin NG, Rice CD, Bear HD. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes. Neurol. Res. 19, 145-152 (1997).
83. Wood GW, Holladay FP, Turner T, Wang YY, Chiga M. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J. Neurooncol. 48, 113-120 (2000).
84. Ishikawa E, Tsuboi K, Saijo K et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24, 1861-1871 (2004).
85. Quattrocchi KB, Miller CH, Cush S et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 45, 141-157 (1999).
86. + T cells. J. Transl. Med. 2, 41 (2004).
87. Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90, 1115-1124 (1999).
88. Okada H, Pollack IF. Cytokine gene therapy for malignant glioma. Expert Opin. Biol. Ther. 4, 1609-1620 (2004).
89. Glick RP, Lichtor T, Cohen EP. Cytokine-based immuno-gene therapy for brain tumors. In: Brain Tumor Immunotherapy. Liau LM, Becker DP, Cloughesy TF, Bigner DD (Eds). Humana Press, NJ, USA, 273-288 (2001).
90. Yu JS, Liu G, Ying H et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64, 4973-4979 (2004).
91. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842-847 (2001).
92. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer 89, 1172-1179 (2003).
93. Yamanaka R, Yajima N, Abe T et al. Dendritic cell-based glioma immunotherapy (review). Int. J. Oncol. 23, 5-15 (2003).
94. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II Trial. Clin. Cancer Res. 11, 4160-4167 (2005).
95. Kikuchi T, Akasaki Y, Irie M et al. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50, 337-344 (2001).
96. Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 27, 452-459 (2004).
97. Caruso DA, Orme LM, Neale AM et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-Oncology 6, 236-246 (2004).
98. Okada H, Lieberman FS, Edington HD et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J. Neurooncol. 64, 13-20 (2003).
99. Ren H, Boulikas T, Lundstrom K et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene - a Phase I/II clinical protocol. J. Neurooncol. 64, 147-154 (2003).
100. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J.Neurooncol. 53, 39-46 (2001).
101. Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol. 22, 4272-4281 (2004).
102. Giezeman-Smits KM, Okada H, Brissette-Storkus CS et al. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4- transfected 9L gliosarcoma is essential for protective immunity. Cancer Res. 60, 2449-2457 (2000).
103. Chabalgoity JA, Dougan G, Mastroeni P, Aspinall RJ. Live bacteria as the basis for immunotherapies against cancer. Expert Rev. Vaccines. 1, 495-505 (2002).
104. Matzinger P. The danger model: a renewed sense of self. Science 296, 301-305 (2002).
105. Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 270, 81-92 (2002).
106. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat. Rev. Immunol. 4, 512-520 (2004).
107. Liau LM, Jensen ER, Kremen TJ et al. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 62, 2287-2293 (2002).
108. Calzascia T, Di Berardino-Besson W, Wilmotte R et al. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J. Immunol. 171, 2187-2191 (2003).
109. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J. Immunother. 25, 218-225 (2002).
110. Clairmont C, Lee KC, Pike J et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J. Infect Dis. 181, 1996-2002 (2000).
111. Toso JF, Gill VJ, Hwu P et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 20, 142-152 (2002).
112. Csatary LK, Gosztonyi G, Szeberenyi J et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. 67, 83-93 (2004).
113. Salgaller ML, Liau LM. Current status of clinical trials for glioblastoma. Reviews on Recent Clinical Trials (1)3, 265-281(17) (2006).
114. Lesniak MS, Gabikian P, Tyler BM, Pardoll DM, Brem H. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J. Neurooncol. 70, 23-28 (2004).
115. Read SB, Kulprathipanja NV, Gomez GG et al. Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-γ or IFN-γ gene modification. J. Interferon Cytokine Res. 23, 379-393 (2003).
116. Badie B, Schartner JM, Paul J et al. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J. Neurosurg. 93, 634-639 (2000).
117. Takagi Y, Kikuchi T, Niimura M, Ohno T. Effects of glucocorticoids on antitumor effects of immunizations with fusions of dendritic and tumor cells. Anticancer Res. 23, 2553-2558 (2003).
118. HLA Peptide Binding Predictions http://bimas.dcrt.nih.gov/molbio/ hla_bind/
119. Department of Immunology, University of Tuebingen www.uni-tuebingen.de/ uni/kxi/
120. Northwest Biotherapeutics www.nwbio.com